Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecnoglutide Phase 2 in Obesity
NCT05111912Phase 2Completed
- Sponsor
- Sciwind Biosciences
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ecnoglutide in obesity, sponsored by Sciwind Biosciences. Primary endpoint: Percentage change in participants body weight from Baseline at Week 26. Started Nov 2021; status: completed.
02
Drugs
ecnoglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05111912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111912.